301096.SZ
百诚医药
SZSE · M 科研服务 · CN
CNY 48.20
−3.15%Year over year
Reported trailing growth
- Revenue
- -0.7%
- EBITDA
- —
- EBIT
- +55.6%
- EPS
- +62.0%
- Free cash flow
- +46.4%
- Operating cash flow
- +36.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.7%
- EBITDA
- -35.6%
- EBIT
- —
- Net income
- -71.4%
- EPS
- -69.4%
- Free cash flow
- +57.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026